AcelRx Pharmaceuticals (NASDAQ:ACRX) : 5 analysts are covering AcelRx Pharmaceuticals (NASDAQ:ACRX) and their average rating on the stock is 1.8, which is read as a Buy. 3 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 2 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
AcelRx Pharmaceuticals (NASDAQ:ACRX) has been rated by 4 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $11 and the lowest price target forecast is $4. The average forecast of all the analysts is $7.31 and the expected standard deviation is $2.98.
For the current week, the company shares have a recommendation consensus of Buy.
AcelRx Pharmaceuticals (NASDAQ:ACRX): stock turned positive on Tuesday. Though the stock opened at $2.5, the bulls momentum made the stock top out at $2.55 level for the day. The stock recorded a low of $2.4 and closed the trading day at $2.5, in the green by 0.81%. The total traded volume for the day was 769,367. The stock had closed at $2.48 in the previous days trading.
In an insider trading activity, The Securities and Exchange Commission has divulged in a Form 4 filing that the CEO of Acelrx Pharmaceuticals Inc, Rosen Howard B had purchased shares worth of $33,272 in a transaction dated on May 13, 2016. A total of 10,206 shares were purchased at a price of $3.26 per share. The information is based on open market trades at the market prices.Option exercises are not covered.
AcelRx Pharmaceuticals, Inc. is a development-stage specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of acute pain. The Companys lead product candidate, Zalviso, is intended for the management of moderate-to-severe acute pain in hospitalized adult patients. Zalviso consists of sufentanil sublingual tablets delivered by the Zalviso System. The Company has three additional product candidates in clinical development: the Sufentanil Sublingual Tablet BTP Management System (ARX-02), a pain management system for the treatment of cancer patients who suffer from Breakthrough Pain (BTP); the Sufentanil/Triazolam Sublingual Tablet (ARX-03), is a single, fixed-dose, combination drug product designed to provide mild sedation, anxiety reduction and pain relief, and Sufentanil Sublingual Single-Dose Acute Pain Tablet (ARX-04) for the treatment of moderate-to-severe acute pain.